STEPHEN YENZEN LAI to Carcinoma, Papillary
This is a "connection" page, showing publications STEPHEN YENZEN LAI has written about Carcinoma, Papillary.
Connection Strength
0.512
-
Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model. Mol Cancer Ther. 2015 Dec; 14(12):2901-8.
Score: 0.098
-
Sialendoscopy for Patients with Radioiodine-Induced Sialadenitis and Xerostomia. Thyroid. 2015 Jul; 25(7):834-8.
Score: 0.096
-
Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb; 100(2):E243-52.
Score: 0.093
-
Detection of thyroid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014 Feb; 99(2):536-44.
Score: 0.087
-
MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul; 9(7):1968-76.
Score: 0.068
-
Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC. J Clin Endocrinol Metab. 2015 Dec; 100(12):E1550-9.
Score: 0.025
-
Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer. Semin Oncol. 2015 Dec; 42(6):915-22.
Score: 0.025
-
Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck. 2014 Mar; 36(3):375-84.
Score: 0.021